Overview

Efficacy of Albumin Dialysis to Treat Patients With Hepatic Encephalopathy Using The Molecular Adsorbent Recirculating System (MARS)

Status:
Completed

Trial end date:
2004-04-01

Target enrollment:

Participant gender:

Summary

The primary objective of the study was to compare the efficacy, safety and tolerability of Extracorporeal Albumin Dialysis (ECAD) using the Molecular Adsorbent Recirculating System (MARS®) device in improving severe HE by 2 grades compared to Standard Medical Therapy (SMT) in patients with chronic End Stage Liver Disease (ESLD) during a 5 day study period.

Phase:

N/A

Details

Lead Sponsor:

Baxter Healthcare Corporation
Gambro Renal Products, Inc.

Collaborator:

Gambro Renal Products, Inc.